|
MXPA06011423A
(es)
|
2004-04-02 |
2007-01-23 |
Osi Pharm Inc |
Inhibidores de proteina cinasa heterobiciclica sustituida en el anillo 6,6-biciclico.
|
|
US9512125B2
(en)
|
2004-11-19 |
2016-12-06 |
The Regents Of The University Of California |
Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents
|
|
CA2630271C
(en)
*
|
2005-11-17 |
2014-04-08 |
Osi Pharmaceuticals, Inc. |
Fused bicyclic mtor inhibitors
|
|
US7772231B2
(en)
*
|
2005-12-29 |
2010-08-10 |
Abbott Laboratories |
Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitors
|
|
EP1981890A2
(en)
*
|
2006-01-25 |
2008-10-22 |
OSI Pharmaceuticals, Inc. |
UNSATURATED mTOR INHIBITORS
|
|
JP2009525046A
(ja)
*
|
2006-01-31 |
2009-07-09 |
エラン ファーマシューティカルズ,インコーポレイテッド |
アルファ−シヌクレインキナーゼ
|
|
KR20150038395A
(ko)
|
2006-04-04 |
2015-04-08 |
더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 |
키나제 길항물질
|
|
US20090023743A1
(en)
*
|
2007-05-09 |
2009-01-22 |
Abbott Laboratories |
Inhibitors of protein kinases
|
|
US8124759B2
(en)
*
|
2007-05-09 |
2012-02-28 |
Abbott Laboratories |
Inhibitors of protein kinases
|
|
US20110160232A1
(en)
|
2007-10-04 |
2011-06-30 |
Pingda Ren |
Certain chemical entities and therapeutic uses thereof
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
BRPI0906473A8
(pt)
|
2008-01-04 |
2016-02-10 |
Intellikine Inc |
Certas entidades químicas, composições e métodos
|
|
EP2247748A2
(en)
*
|
2008-02-13 |
2010-11-10 |
Elan Pharma International Limited |
Alpha-synuclein kinase
|
|
US8993580B2
(en)
|
2008-03-14 |
2015-03-31 |
Intellikine Llc |
Benzothiazole kinase inhibitors and methods of use
|
|
WO2009114870A2
(en)
*
|
2008-03-14 |
2009-09-17 |
Intellikine, Inc. |
Kinase inhibitors and methods of use
|
|
MX2010010300A
(es)
*
|
2008-03-19 |
2010-10-26 |
Osi Pharm Inc |
Formas de sal de inhibidores del objetivo de rapamicina en mamiferos.
|
|
CL2009000904A1
(es)
|
2008-04-21 |
2010-04-30 |
Shionogi & Co |
Compuestos derivados de ciclohexil sulfonamidas que tienen actividad antagonista en el receptor npy y5, composicion farmaceutica y formulacion farmaceutica que los comprende.
|
|
ES2396613T3
(es)
|
2008-05-19 |
2013-02-22 |
OSI Pharmaceuticals, LLC |
Imidazopirazinas e imidazotriazinas sustituidas
|
|
AU2009257602B2
(en)
*
|
2008-06-10 |
2015-10-08 |
Abbvie Inc. |
Novel tricyclic compounds
|
|
EP2313102A2
(en)
|
2008-07-03 |
2011-04-27 |
Biota Scientific Management |
Bycyclic nucleosides and nucleotides as therapeutic agents
|
|
US20110224223A1
(en)
|
2008-07-08 |
2011-09-15 |
The Regents Of The University Of California, A California Corporation |
MTOR Modulators and Uses Thereof
|
|
MX2011000216A
(es)
|
2008-07-08 |
2011-03-29 |
Intellikine Inc |
Inhibidores de cinasa y metodos para su uso.
|
|
WO2010036380A1
(en)
|
2008-09-26 |
2010-04-01 |
Intellikine, Inc. |
Heterocyclic kinase inhibitors
|
|
AU2009305669A1
(en)
|
2008-10-16 |
2010-04-22 |
The Regents Of The University Of California |
Fused ring heteroaryl kinase inhibitors
|
|
US8476431B2
(en)
*
|
2008-11-03 |
2013-07-02 |
Itellikine LLC |
Benzoxazole kinase inhibitors and methods of use
|
|
EP2421837A1
(en)
|
2009-04-20 |
2012-02-29 |
OSI Pharmaceuticals, LLC |
Preparation of c-pyrazine-methylamines
|
|
JP5789252B2
(ja)
|
2009-05-07 |
2015-10-07 |
インテリカイン, エルエルシー |
複素環式化合物およびその使用
|
|
US8980899B2
(en)
|
2009-10-16 |
2015-03-17 |
The Regents Of The University Of California |
Methods of inhibiting Ire1
|
|
WO2011064211A1
(en)
|
2009-11-25 |
2011-06-03 |
Novartis Ag |
Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
|
|
EP4782062A2
(en)
|
2009-12-01 |
2026-07-29 |
AbbVie Inc. |
Novel tricyclic compounds
|
|
JP2013512282A
(ja)
|
2009-12-01 |
2013-04-11 |
アボット・ラボラトリーズ |
新規三環式化合物
|
|
US20130005733A1
(en)
|
2010-03-09 |
2013-01-03 |
OSI Pharmaceuticals, LLC |
Combination anti-cancer therapy
|
|
JP5951600B2
(ja)
|
2010-05-21 |
2016-07-13 |
インフィニティー ファーマシューティカルズ, インコーポレイテッド |
キナーゼ調節のための、化合物、組成物および方法
|
|
WO2011156698A2
(en)
*
|
2010-06-11 |
2011-12-15 |
Abbott Laboratories |
NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS
|
|
WO2012064973A2
(en)
|
2010-11-10 |
2012-05-18 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
EP3238722B1
(en)
|
2011-01-10 |
2019-03-13 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinones
|
|
TWI592411B
(zh)
|
2011-02-23 |
2017-07-21 |
英特爾立秦有限責任公司 |
激酶抑制劑之組合及其用途
|
|
WO2012135631A1
(en)
*
|
2011-03-30 |
2012-10-04 |
Arrien Pharmaeuticals Llc |
Substituted 5-(pyrazin-2-yl)-1h-pyrazolo [3, 4-b] pyridine and pyrazolo [3, 4-b] pyridine derivatives as protein kinase inhibitors
|
|
WO2013004551A1
(en)
|
2011-07-01 |
2013-01-10 |
Bayer Intellectual Property Gmbh |
Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors
|
|
US9056877B2
(en)
|
2011-07-19 |
2015-06-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
EP2734520B1
(en)
|
2011-07-19 |
2016-09-14 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
PE20141371A1
(es)
|
2011-08-29 |
2014-10-13 |
Infinity Pharmaceuticals Inc |
Compuestos heterociclicos y usos de los mismos
|
|
WO2013077921A2
(en)
|
2011-09-02 |
2013-05-30 |
The Regents Of The University Of California |
Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
|
|
ES2619829T3
(es)
|
2011-11-18 |
2017-06-27 |
Heptares Therapeutics Limited |
Agonistas del receptor muscarínico M1
|
|
UY34484A
(es)
|
2011-12-15 |
2013-07-31 |
Bayer Ip Gmbh |
Benzotienilo-pirrolotriazinas disustituidas y sus usos
|
|
CA2865021C
(en)
|
2012-02-23 |
2020-06-30 |
Bayer Intellectual Property Gmbh |
Substituted benzothienyl-pyrrolotriazines and uses thereof
|
|
US8940742B2
(en)
|
2012-04-10 |
2015-01-27 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
US8828998B2
(en)
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
|
CA2886240A1
(en)
|
2012-09-26 |
2014-04-03 |
The Regents Of The University Of California |
Modulation of ire1
|
|
RU2702908C2
(ru)
|
2012-11-01 |
2019-10-14 |
Инфинити Фармасьютикалз, Инк. |
Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
|
|
US9481667B2
(en)
|
2013-03-15 |
2016-11-01 |
Infinity Pharmaceuticals, Inc. |
Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
|
|
EP2976086B1
(en)
|
2013-03-22 |
2020-10-14 |
Millennium Pharmaceuticals, Inc. |
Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
|
|
WO2015051241A1
(en)
|
2013-10-04 |
2015-04-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
EP3964507A1
(en)
|
2013-10-04 |
2022-03-09 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
GB201404922D0
(en)
|
2014-03-19 |
2014-04-30 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
|
CN106456628A
(zh)
|
2014-03-19 |
2017-02-22 |
无限药品股份有限公司 |
用于治疗PI3K‑γ介导的障碍的杂环化合物
|
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
WO2016054491A1
(en)
|
2014-10-03 |
2016-04-07 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
WO2016064958A1
(en)
|
2014-10-22 |
2016-04-28 |
Bristol-Myers Squibb Company |
Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors
|
|
EP3209664B1
(en)
|
2014-10-22 |
2020-06-03 |
Bristol-Myers Squibb Company |
Bicyclic heteroaryl amine compounds as pi3k inhibitors
|
|
GB201513743D0
(en)
|
2015-08-03 |
2015-09-16 |
Heptares Therapeutics Ltd |
Muscarinic agonists
|
|
CN114230571B
(zh)
|
2015-09-14 |
2025-07-08 |
无限药品股份有限公司 |
异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
|
|
US11365198B2
(en)
|
2015-10-16 |
2022-06-21 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US10550126B2
(en)
|
2015-10-16 |
2020-02-04 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US12365689B2
(en)
|
2015-10-16 |
2025-07-22 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11524964B2
(en)
|
2015-10-16 |
2022-12-13 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
CN116270646A
(zh)
|
2015-10-16 |
2023-06-23 |
艾伯维公司 |
制备咪唑并[1,2-a]吡咯并[2,3-e]吡嗪类化合物及其固态形式的方法
|
|
US11512092B2
(en)
|
2015-10-16 |
2022-11-29 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
|
|
US11780848B2
(en)
|
2015-10-16 |
2023-10-10 |
Abbvie Inc. |
Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1- carboxamide and solid state forms thereof
|
|
GB201519352D0
(en)
|
2015-11-02 |
2015-12-16 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
|
WO2017161116A1
(en)
|
2016-03-17 |
2017-09-21 |
Infinity Pharmaceuticals, Inc. |
Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
|
|
TWI828027B
(zh)
|
2016-03-28 |
2024-01-01 |
美商英塞特公司 |
作為tam抑制劑之吡咯并三嗪化合物
|
|
HRP20221051T8
(hr)
|
2016-04-15 |
2023-07-21 |
Cancer Research Technology Limited |
Heterociklički spojevi kao inhibitori ret kinaze
|
|
KR102706837B1
(ko)
|
2016-04-15 |
2024-09-19 |
캔써 리서치 테크놀로지 리미티드 |
Ret 키나아제 억제제로서의 헤테로사이클릭 화합물
|
|
US10919914B2
(en)
|
2016-06-08 |
2021-02-16 |
Infinity Pharmaceuticals, Inc. |
Heterocyclic compounds and uses thereof
|
|
EP3474856B1
(en)
|
2016-06-24 |
2022-09-14 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
GB201617454D0
(en)
|
2016-10-14 |
2016-11-30 |
Heptares Therapeutics Limited |
Pharmaceutical compounds
|
|
US10259787B2
(en)
|
2016-10-14 |
2019-04-16 |
Heptares Therapeutics Limited |
Substituted cyclohexanes as muscarinic M1 receptor and/or M4 receptor agonists
|
|
SG10202106949XA
(en)
|
2016-11-18 |
2021-07-29 |
Cystic Fibrosis Found |
Pyrrolopyrimidines as cftr potentiators
|
|
CN110300589B
(zh)
*
|
2016-12-16 |
2023-03-10 |
囊性纤维化基金会 |
作为cftr增效剂的双环异杂芳基衍生物
|
|
CN110392572A
(zh)
|
2017-03-09 |
2019-10-29 |
艾伯维公司 |
治疗克罗恩病和溃疡性结肠炎的方法
|
|
US11564922B2
(en)
|
2017-03-09 |
2023-01-31 |
Abbvie Inc. |
Methods of treating crohn's disease and ulcerative colitis
|
|
GB201705971D0
(en)
*
|
2017-04-13 |
2017-05-31 |
Cancer Res Tech Ltd |
Inhibitor compounds
|
|
GB201810239D0
(en)
|
2018-06-22 |
2018-08-08 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
|
GB201819960D0
(en)
|
2018-12-07 |
2019-01-23 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
|
GB201819961D0
(en)
|
2018-12-07 |
2019-01-23 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
|
EP3917929A1
(en)
*
|
2019-01-31 |
2021-12-08 |
Bayer Aktiengesellschaft |
The monohydrate of rogaratinib hydrochloride and solid states thereof
|
|
GB202020191D0
(en)
|
2020-12-18 |
2021-02-03 |
Heptares Therapeutics Ltd |
Pharmaceutical compounds
|
|
KR20220050126A
(ko)
|
2019-06-12 |
2022-04-22 |
티엠이엠16에이 리미티드 |
호흡기 질환을 치료하기 위한 화합물
|
|
JP2022545835A
(ja)
|
2019-08-28 |
2022-10-31 |
ホライゾン セラピューティクス アイルランド デジグネイテッド アクティビティ カンパニー |
甲状腺眼症の治療方法
|
|
AU2020436612A1
(en)
*
|
2020-03-16 |
2022-09-01 |
Flash Therapeutics, Llc |
Compounds for treating or inhibiting recurrence of acute myeloid leukemia
|
|
CN122003247A
(zh)
|
2023-07-07 |
2026-05-08 |
维里迪安治疗公司 |
治疗活动性和慢性甲状腺眼病的方法
|